LAE Biotech LAE Biotech LAE Biotech
side menu

Glycotope Antibody
Glycotope SAb

TOPO I Assay Kit
TOPO I Drug Screen Kit
TOPO IIa Antibody
TOPO IIb Antibody

Phosphatase Inhibitor-1
Phospho- Inhibitor-1
Phosphatase Inhibitor-2
Phosphatase Inhibitor-2 Ab

GnRH I Antibody
ACTH Antibody
HER II Receptor Antibody

Price List
Customized Service
How To Order


Taivital Biopharmaceutical Co., Ltd. was established using the novel technology platform "Linear array epitope (LAE) technology", developed by Dr. Jaulang Hwang and Dr. Chiajer Hsu for therapeutic vaccine and immunogen design. This novel LAE technology significantly improves the antigenicity of immunogen, enabling the successful development of many low antigenic immunogen.  The company's mission is to apply LAE technology in the biopharmaceutical industry, and combined with domestic and foreign professionals in biotech medicine and academic community to work together, looking forward to becoming a world-class innovative biopharmaceutical company, engaged in therapeutic vaccine and IVD antibody development, is expected to be applied to a variety of disease diagnsis, treatment and prevention.

The company's business policy is first of all the development, production and sale of in vitro diagnostic antibodies; First there is gold flow in to improve the financial, and then gradually support the follow-up development of biologics (antibody drugs and therapeutical vaccines), clinical trials and obtaining drug licens. The company will continue to actively seek the international strategic alliance of well established pharmaceutical companies, accelerate internationalization and expansion of the scale of operations, in order to safeguard human health and well-being.



台灣活力生技新藥股份有限公司的創立是基於黃昭蓮博士與徐嘉澤博士共同開發之原創技術平台「模版重複聚合酶連鎖反應」 (linear array epitope technology; LAE technology),可大幅提升疫苗之抗原性,使許多低抗原性標的疫苗得以成功開發。

本公司的使命是應用LAE technology於生技製藥產業,並結合國內外學有專精的生技醫藥界及學界人士共同努力,期望成為世界級的創新生技新藥公司,從事生物製劑及抗體開發,預期應用於各種疾病檢驗、治療及預防。